Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × NSCLC × Gefitinib × Clear all

Phase

Phase 2/3 2 Phase NA 1 Phase 3 1 Phase 2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 14 Unspecified Adult Solid Tumor, Protocol Specific 3 Lung Neoplasms 3 Squamous Cell Carcinoma of Head and Neck 2 Head and Neck Neoplasms 2 Unspecified Childhood Solid Tumor, Protocol Specific 1 Solid Tumors 1 Rectal Neoplasms 1 Oligodendroglioma 1 Neoplasms 1 NSCLC 1 Lymphoma 1 Gliosarcoma 1 Glioma 1 Glioblastoma 1 EGFR-mutant Non-small Cell Lung Cancer 1 Colorectal Neoplasms 1 Colonic Neoplasms 1 Central Nervous System Neoplasms 1 Carcinoma, Squamous Cell 1 Brain Neoplasms 1 Astrocytoma 1 Advanced Tumor 1 Adenocarcinoma, Bronchiolo-Alveolar 1 Adenocarcinoma of Lung 1

Interventions

aflutinib 3 osimertinib 2 Radiotherapy 2 tipifarnib 1 apatinib 1 Radiosurgery 1 Immune Checkpoint Inhibitors 1 Gefitinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04390984 2021-01-11

Drug-drug Interaction Study of Gefitinb on Apatinib in NSCLC Patients

Jiangsu HengRui Medicine Co., Ltd.

Phase 1 Unknown

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡